Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium.

Angelo V. Marzano, Stefano Ramoni, Diana Spinelli, Elvio Alessi, Emilio Berti

Research output: Contribution to journalArticle

Abstract

Linear IgA bullous dermatosis (LABD) is a rare, blistering autoimmune disease characterized by linear deposits of IgA at the basement membrane zone (BMZ), with the possible presence of circulating IgA anti-BMZ antibodies. LABD of childhood is usually self-healing, while in adults it follows a more prolonged course and refractory cases may rarely occur. The first-line treatment for LABD is dapsone in monotherapy or in combination with systemic corticosteroids, but various therapeutic approaches have been used in non-responder patients. We report two adult patients with refractory LABD successfully treated with enteric-coated mycophenolate sodium (EC-MPS), a recently introduced formulation of mycophenolic acid (MPA). MPA is an immunosuppressive agent that acts by inhibiting monophosphate dehydrogenase, a key enzyme in the novo synthesis of purines. Based on the present cases, we indicate EC-MPS as being a safe and effective adjuvant therapy in the treatment of LABD when dapsone or the other steroid-sparing drugs fail. It seems to offer an improved gastric side effect profile in comparison with the classic formulation of MPA, namely its ester mycophenolate mofetil (MMF).

Original languageEnglish
Pages (from-to)364-367
Number of pages4
JournalJournal of Dermatological Treatment
Volume19
Issue number6
Publication statusPublished - 2008

Fingerprint

Linear IgA Bullous Dermatosis
Mycophenolic Acid
Dapsone
Basement Membrane
Purines
Therapeutics
Immunosuppressive Agents
Immunoglobulin A
Autoimmune Diseases
Stomach
Adrenal Cortex Hormones
Oxidoreductases
Esters
Steroids
Antibodies
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. / Marzano, Angelo V.; Ramoni, Stefano; Spinelli, Diana; Alessi, Elvio; Berti, Emilio.

In: Journal of Dermatological Treatment, Vol. 19, No. 6, 2008, p. 364-367.

Research output: Contribution to journalArticle

@article{de3fa09ffa454414b1e93b4a19f36645,
title = "Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium.",
abstract = "Linear IgA bullous dermatosis (LABD) is a rare, blistering autoimmune disease characterized by linear deposits of IgA at the basement membrane zone (BMZ), with the possible presence of circulating IgA anti-BMZ antibodies. LABD of childhood is usually self-healing, while in adults it follows a more prolonged course and refractory cases may rarely occur. The first-line treatment for LABD is dapsone in monotherapy or in combination with systemic corticosteroids, but various therapeutic approaches have been used in non-responder patients. We report two adult patients with refractory LABD successfully treated with enteric-coated mycophenolate sodium (EC-MPS), a recently introduced formulation of mycophenolic acid (MPA). MPA is an immunosuppressive agent that acts by inhibiting monophosphate dehydrogenase, a key enzyme in the novo synthesis of purines. Based on the present cases, we indicate EC-MPS as being a safe and effective adjuvant therapy in the treatment of LABD when dapsone or the other steroid-sparing drugs fail. It seems to offer an improved gastric side effect profile in comparison with the classic formulation of MPA, namely its ester mycophenolate mofetil (MMF).",
author = "Marzano, {Angelo V.} and Stefano Ramoni and Diana Spinelli and Elvio Alessi and Emilio Berti",
year = "2008",
language = "English",
volume = "19",
pages = "364--367",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium.

AU - Marzano, Angelo V.

AU - Ramoni, Stefano

AU - Spinelli, Diana

AU - Alessi, Elvio

AU - Berti, Emilio

PY - 2008

Y1 - 2008

N2 - Linear IgA bullous dermatosis (LABD) is a rare, blistering autoimmune disease characterized by linear deposits of IgA at the basement membrane zone (BMZ), with the possible presence of circulating IgA anti-BMZ antibodies. LABD of childhood is usually self-healing, while in adults it follows a more prolonged course and refractory cases may rarely occur. The first-line treatment for LABD is dapsone in monotherapy or in combination with systemic corticosteroids, but various therapeutic approaches have been used in non-responder patients. We report two adult patients with refractory LABD successfully treated with enteric-coated mycophenolate sodium (EC-MPS), a recently introduced formulation of mycophenolic acid (MPA). MPA is an immunosuppressive agent that acts by inhibiting monophosphate dehydrogenase, a key enzyme in the novo synthesis of purines. Based on the present cases, we indicate EC-MPS as being a safe and effective adjuvant therapy in the treatment of LABD when dapsone or the other steroid-sparing drugs fail. It seems to offer an improved gastric side effect profile in comparison with the classic formulation of MPA, namely its ester mycophenolate mofetil (MMF).

AB - Linear IgA bullous dermatosis (LABD) is a rare, blistering autoimmune disease characterized by linear deposits of IgA at the basement membrane zone (BMZ), with the possible presence of circulating IgA anti-BMZ antibodies. LABD of childhood is usually self-healing, while in adults it follows a more prolonged course and refractory cases may rarely occur. The first-line treatment for LABD is dapsone in monotherapy or in combination with systemic corticosteroids, but various therapeutic approaches have been used in non-responder patients. We report two adult patients with refractory LABD successfully treated with enteric-coated mycophenolate sodium (EC-MPS), a recently introduced formulation of mycophenolic acid (MPA). MPA is an immunosuppressive agent that acts by inhibiting monophosphate dehydrogenase, a key enzyme in the novo synthesis of purines. Based on the present cases, we indicate EC-MPS as being a safe and effective adjuvant therapy in the treatment of LABD when dapsone or the other steroid-sparing drugs fail. It seems to offer an improved gastric side effect profile in comparison with the classic formulation of MPA, namely its ester mycophenolate mofetil (MMF).

UR - http://www.scopus.com/inward/record.url?scp=59649115003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649115003&partnerID=8YFLogxK

M3 - Article

C2 - 19016105

AN - SCOPUS:59649115003

VL - 19

SP - 364

EP - 367

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 6

ER -